Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ILB 202

Next Previous
X
Search
Drug Profile

ILB 202

Alternative Names: Exo-srIκBs; ILB-202; srIκB; super-repressor IκB

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ILIAS Biologics
  • Developer ILIAS Biologics; Yonsei University
  • Class Anti-inflammatories; Antiseptics; Exosome therapies; Gene therapies; Proteins
  • Mechanism of Action NF-kappa B inhibitors; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Inflammation; Unspecified
  • Preclinical Acute kidney injury; Preterm labour
  • No development reported Sepsis

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Sepsis in South Korea (Intraperitoneal, Injection)
  • 05 Sep 2023 ILIAS Biologics completes a phase I trial in healthy volunteers in Australia (IV) (NCT05843799)
  • 16 May 2023 Phase-I clinical trials in Unspecified (In volunteers, In adults) in Australia (IV) (NCT05843799)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top